Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity
Purpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it. Methods. This retrospective case series was carried out at the “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoc...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2015/102582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566965093269504 |
|---|---|
| author | Simona Delia Nicoară Constanța Nascutzy Cristina Cristian Iulian Irimescu Anne Claudia Ștefănuț Gabriela Zaharie Tudor Drugan |
| author_facet | Simona Delia Nicoară Constanța Nascutzy Cristina Cristian Iulian Irimescu Anne Claudia Ștefănuț Gabriela Zaharie Tudor Drugan |
| author_sort | Simona Delia Nicoară |
| collection | DOAJ |
| description | Purpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it. Methods. This retrospective case series was carried out at the “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania. It includes all the consecutive infants treated for ROP with one intravitreal bevacizumab injection, from January 1, 2009, throughout July 31, 2013. The follow-up continued for 60 weeks after injection. We recorded ROP classification, regression, gender, gestational age, birth weight, postnatal age and postmenstrual age at treatment, and pregnancy type. Regression was analyzed according to each of the abovementioned factors, with the program IBM SPSS 20 (Chicago, Illinois, USA). Results. This study includes 74 eyes of 37 infants of which 52 had aggressive posterior ROP (70.27%) and 22 had zone I stage 3+ ROP (29.72%). One week after the bevacizumab injection, ROP regressed in 63 eyes (85.13%), with a statistically significant higher rate in zone I stage 3+ ROP (100%), as compared with aggressive posterior ROP (78.84%) (P=0.03). We recorded no complications subsequent to the intravitreal injections of bevacizumab. We identified no late retinal detachment. Conclusion. ROP regression rate after one intravitreal bevacizumab injection was 85.13%. This trial is registered with trial registration number IRCT2014101618966N2. |
| format | Article |
| id | doaj-art-889c34fec457416bb43ad95b1ba48692 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-889c34fec457416bb43ad95b1ba486922025-02-03T01:02:42ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/102582102582Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of PrematuritySimona Delia Nicoară0Constanța Nascutzy1Cristina Cristian2Iulian Irimescu3Anne Claudia Ștefănuț4Gabriela Zaharie5Tudor Drugan6Department of Ophthalmology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, Romania“Alfred Rusescu” Institute for Mother and Child Care, 120 Lacul Tei Boulevard, 020395 Bucharest, RomaniaDepartment of Ophthalmology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, RomaniaDepartment of Neuroscience, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, RomaniaDepartment of Ophthalmology, Emergency County Hospital, 3-5 Clinicilor Street, 400006 Cluj-Napoca, RomaniaDepartment of Neonatology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, RomaniaDepartment of Medical Informatics and Biostatistics, “Iuliu Hațieganu” University of Medicine and Pharmacy, 8 Victor Babeș Street, 400012 Cluj-Napoca, RomaniaPurpose. This study aims to evaluate the regression of retinopathy of prematurity (ROP) after one intravitreal injection of bevacizumab and the factors that influenced it. Methods. This retrospective case series was carried out at the “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania. It includes all the consecutive infants treated for ROP with one intravitreal bevacizumab injection, from January 1, 2009, throughout July 31, 2013. The follow-up continued for 60 weeks after injection. We recorded ROP classification, regression, gender, gestational age, birth weight, postnatal age and postmenstrual age at treatment, and pregnancy type. Regression was analyzed according to each of the abovementioned factors, with the program IBM SPSS 20 (Chicago, Illinois, USA). Results. This study includes 74 eyes of 37 infants of which 52 had aggressive posterior ROP (70.27%) and 22 had zone I stage 3+ ROP (29.72%). One week after the bevacizumab injection, ROP regressed in 63 eyes (85.13%), with a statistically significant higher rate in zone I stage 3+ ROP (100%), as compared with aggressive posterior ROP (78.84%) (P=0.03). We recorded no complications subsequent to the intravitreal injections of bevacizumab. We identified no late retinal detachment. Conclusion. ROP regression rate after one intravitreal bevacizumab injection was 85.13%. This trial is registered with trial registration number IRCT2014101618966N2.http://dx.doi.org/10.1155/2015/102582 |
| spellingShingle | Simona Delia Nicoară Constanța Nascutzy Cristina Cristian Iulian Irimescu Anne Claudia Ștefănuț Gabriela Zaharie Tudor Drugan Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity Journal of Ophthalmology |
| title | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity |
| title_full | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity |
| title_fullStr | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity |
| title_full_unstemmed | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity |
| title_short | Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity |
| title_sort | outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone i stage 3 and aggressive posterior retinopathy of prematurity |
| url | http://dx.doi.org/10.1155/2015/102582 |
| work_keys_str_mv | AT simonadelianicoara outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity AT constantanascutzy outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity AT cristinacristian outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity AT iulianirimescu outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity AT anneclaudiastefanut outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity AT gabrielazaharie outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity AT tudordrugan outcomesandprognosticfactorsofintravitrealbevacizumabmonotherapyinzoneistage3andaggressiveposteriorretinopathyofprematurity |